Personalized Medicines Will Help Vendors Gain a Competitive Edge in the Lung Cancer Therapeutics Market by 2019: TechNavio

LONDON--()--The high unmet need for personalized drugs has propelled growth in the Global Lung Cancer Therapeutics Market, which is expected to post a CAGR of 3.80 percent from 2015-2019, says research firm TechNavio.

There is currently no cure for lung cancer. Hence, drugs that lead to remission in patients are expected to significantly drive market growth.

About the Report

The latest report from TechNavio emphasizes the increased adoption of personalized medicine, which provides more specific and targeted therapy, varying from person to person. Personalized medicine is dependent on the genetic structure of the patient and can be developed accordingly.

Genentech, a subsidiary of F. Hoffmann-La Roche, obtained approval for Tarceva, which is the first FDA approved therapy for the treatment of non-small cell lung cancer in the US. It is approved for the indication of Epidermal Growth Factor Receptor (EGFR) mutation-positive metastatic non-small cell lung cancer.

“Research efforts and investments are expected to increase as organizations like the Lung Cancer Alliance in the US generate awareness of the disease,” says Faisal Ghaus, Vice President of TechNavio.

“These associations provide support to patients in terms of access to medicines and reimbursement for testing and diagnosis of the disease. Additionally, they provide funding for research related to lung cancer, which will ultimately help the Lung Cancer Therapeutics Market grow through the projected period. ”

Key Information Covered in the Report:

  • Market segmentation, size and forecast through 2019
  • Market Growth Drivers:
  • Market Challenges:
  • Market Trends:
  • Key Vendors:
    • AstraZeneca plc
    • Celgene Corp.
    • Eli Lilly and Co.
  • Other Prominent Vendors:
    • Agennix
    • Amgen
    • Boehringer Ingelheim
    • Celldex

TechNavio currently has more than 3000 market research reports on a huge range of topics, including 100+ reports on the therapeutics market:

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

TechNavio Research
Jes Ellacott, Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
media@technavio.com

Release Summary

According to research firm TechNavio, the Global Lung Cancer Therapeutics Market is expected to post a CAGR of 3.80 percent from 2015-2019.

Contacts

TechNavio Research
Jes Ellacott, Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
media@technavio.com